Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2

Paolo De Paoli, Stefania Zanussi, Laura Caggiari, Maria Teresa Bortolin, Monica D'Andrea, Cecilia Simonelli, Umberto Tirelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study presents the kinetics of CD4/CD25 cell numbers, serum sCD25 levels, and intracellular production and release of interleukin-2 (IL-2) and interleukin-16 (IL-16) in 11 HIV+ patients treated with six cycles of highly active antiretroviral therapy (HAART) plus six MUI of subcutaneous IL-2 compared to 10 HIV+ patients treated with HAART alone. IL-2 therapy induced moderate effects on CD4 T cell recovery and increased CD4/CD25+ cells and sCD25 levels after 2 weeks, while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point. After 24 weeks, while HAART- treated patients had increased IL-2 production, in IL-2 treated patients, cytokine production was unaltered compared to pretreatment values: Decreased in vitro IL-2 production may depend on a feedback inhibition by IL-2 infusion. Because of its known antiviral effects, the increased IL-16 production seen after 2 weeks in IL-2-treated individuals may produce beneficial effects on HIV disease. The kinetics of cytokine production may serve to define better the use IL-2 in clinical trials.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalJournal of Clinical Immunology
Volume19
Issue number5
DOIs
Publication statusPublished - 1999

Fingerprint

Lymphokines
Highly Active Antiretroviral Therapy
Interleukin-2
HIV
Interleukin-16
Cytokines
Antiviral Agents
Cell Count
Clinical Trials
T-Lymphocytes

Keywords

  • Highly active antiretroviral therapy
  • HIV infection
  • IL-16
  • IL-2 production
  • IL-2 therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. / De Paoli, Paolo; Zanussi, Stefania; Caggiari, Laura; Bortolin, Maria Teresa; D'Andrea, Monica; Simonelli, Cecilia; Tirelli, Umberto.

In: Journal of Clinical Immunology, Vol. 19, No. 5, 1999, p. 317-325.

Research output: Contribution to journalArticle

De Paoli, Paolo ; Zanussi, Stefania ; Caggiari, Laura ; Bortolin, Maria Teresa ; D'Andrea, Monica ; Simonelli, Cecilia ; Tirelli, Umberto. / Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. In: Journal of Clinical Immunology. 1999 ; Vol. 19, No. 5. pp. 317-325.
@article{aa23b122548746c9bb72c1fef6db4e08,
title = "Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2",
abstract = "This study presents the kinetics of CD4/CD25 cell numbers, serum sCD25 levels, and intracellular production and release of interleukin-2 (IL-2) and interleukin-16 (IL-16) in 11 HIV+ patients treated with six cycles of highly active antiretroviral therapy (HAART) plus six MUI of subcutaneous IL-2 compared to 10 HIV+ patients treated with HAART alone. IL-2 therapy induced moderate effects on CD4 T cell recovery and increased CD4/CD25+ cells and sCD25 levels after 2 weeks, while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point. After 24 weeks, while HAART- treated patients had increased IL-2 production, in IL-2 treated patients, cytokine production was unaltered compared to pretreatment values: Decreased in vitro IL-2 production may depend on a feedback inhibition by IL-2 infusion. Because of its known antiviral effects, the increased IL-16 production seen after 2 weeks in IL-2-treated individuals may produce beneficial effects on HIV disease. The kinetics of cytokine production may serve to define better the use IL-2 in clinical trials.",
keywords = "Highly active antiretroviral therapy, HIV infection, IL-16, IL-2 production, IL-2 therapy",
author = "{De Paoli}, Paolo and Stefania Zanussi and Laura Caggiari and Bortolin, {Maria Teresa} and Monica D'Andrea and Cecilia Simonelli and Umberto Tirelli",
year = "1999",
doi = "10.1023/A:1020547826191",
language = "English",
volume = "19",
pages = "317--325",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2

AU - De Paoli, Paolo

AU - Zanussi, Stefania

AU - Caggiari, Laura

AU - Bortolin, Maria Teresa

AU - D'Andrea, Monica

AU - Simonelli, Cecilia

AU - Tirelli, Umberto

PY - 1999

Y1 - 1999

N2 - This study presents the kinetics of CD4/CD25 cell numbers, serum sCD25 levels, and intracellular production and release of interleukin-2 (IL-2) and interleukin-16 (IL-16) in 11 HIV+ patients treated with six cycles of highly active antiretroviral therapy (HAART) plus six MUI of subcutaneous IL-2 compared to 10 HIV+ patients treated with HAART alone. IL-2 therapy induced moderate effects on CD4 T cell recovery and increased CD4/CD25+ cells and sCD25 levels after 2 weeks, while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point. After 24 weeks, while HAART- treated patients had increased IL-2 production, in IL-2 treated patients, cytokine production was unaltered compared to pretreatment values: Decreased in vitro IL-2 production may depend on a feedback inhibition by IL-2 infusion. Because of its known antiviral effects, the increased IL-16 production seen after 2 weeks in IL-2-treated individuals may produce beneficial effects on HIV disease. The kinetics of cytokine production may serve to define better the use IL-2 in clinical trials.

AB - This study presents the kinetics of CD4/CD25 cell numbers, serum sCD25 levels, and intracellular production and release of interleukin-2 (IL-2) and interleukin-16 (IL-16) in 11 HIV+ patients treated with six cycles of highly active antiretroviral therapy (HAART) plus six MUI of subcutaneous IL-2 compared to 10 HIV+ patients treated with HAART alone. IL-2 therapy induced moderate effects on CD4 T cell recovery and increased CD4/CD25+ cells and sCD25 levels after 2 weeks, while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point. After 24 weeks, while HAART- treated patients had increased IL-2 production, in IL-2 treated patients, cytokine production was unaltered compared to pretreatment values: Decreased in vitro IL-2 production may depend on a feedback inhibition by IL-2 infusion. Because of its known antiviral effects, the increased IL-16 production seen after 2 weeks in IL-2-treated individuals may produce beneficial effects on HIV disease. The kinetics of cytokine production may serve to define better the use IL-2 in clinical trials.

KW - Highly active antiretroviral therapy

KW - HIV infection

KW - IL-16

KW - IL-2 production

KW - IL-2 therapy

UR - http://www.scopus.com/inward/record.url?scp=0032882119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032882119&partnerID=8YFLogxK

U2 - 10.1023/A:1020547826191

DO - 10.1023/A:1020547826191

M3 - Article

VL - 19

SP - 317

EP - 325

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 5

ER -